Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide

By Gerstner Elizabeth   Eichler April   Plotkin Scott   Drappatz Jan   Doyle Colin   Xu Lei   Duda Dan   Wen Patrick   Jain Rakesh   Batchelor Tracy  

Journal of Neuro-Oncology, Vol. 103, Iss. 2, 2011-06 ,pp. : 325-332

Springer Publishing Company

Access to resources Recommend Favorite

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

By Reardon David   Vredenburgh James   Desjardins Annick   Peters Katherine   Gururangan Sridharan   Sampson John   Marcello Jennifer   Herndon James   McLendon Roger   Janney Dorothea   Friedman Allan   Bigner Darell   Friedman Henry  

Journal of Neuro-Oncology, Vol. 101, Iss. 1, 2011-01 ,pp. : 57-66

Springer Publishing Company

Access to resources Recommend Favorite

Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy

By Shi Yan  

Tumor Biology, Vol. 32, Iss. 2, 2011-04 ,pp. : 381-390

Springer Publishing Company

Access to resources Recommend Favorite

Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy

By Wilop Stefan   Hobe Sabine   Crysandt Martina   Esser Albert   Osieka Rainhardt   Jost Edgar  

Journal of Cancer Research and Clinical Oncology, Vol. 135, Iss. 10, 2009-10 ,pp. : 1429-1435

Springer Publishing Company

Access to resources Recommend Favorite

Inhibition of the enzyme activity of cytochrome P450 1A1, 1A2 and 3A4 by fucoxanthin, a marine carotenoid

By    

Oncology Letters, Vol. 6, Iss. 3, 2013-01 ,pp. : 860-864

Spandidos Publications

Access to resources Recommend Favorite